Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial
- 24 January 2007
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 106 (2) , 229-238
- https://doi.org/10.1007/s10549-006-9483-6
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Economic burden associated with breast cancer recurrenceCancer, 2006
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004Journal of Clinical Oncology, 2005
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancerThe Lancet, 2005
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancerCancer, 2003
- Local-Regional Breast Cancer Recurrence: Prognostic Groups Based on Patterns of FailureThe Breast Journal, 2002
- Safety and efficacy of antiestrogens for prevention of breast cancerAmerican Journal of Health-System Pharmacy, 2000
- Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancerCancer Treatment Reviews, 2000
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Pattern of dissemination and survival following isolated locoregional recurrence of breast cancerBreast Cancer Research and Treatment, 1997
- Markov Models in Medical Decision MakingMedical Decision Making, 1993